Results presented at ASCO demonstrating the synergy of PharmaMar’s combination of lurbinectedin with irinotecan in patients with relapsed small cell lung cancer

The combination of PharmaMar’s lurbinectedin and irinotecan showed that 52.7% of patients treated with relapsed Small Cell Lung Cancer with a chemotherapy-free interval greater than 30 days attained an objective response (tumour shrinkage of ≥30%) from treatment. The study was presented at the world’s largest clinical oncology congress held in Chicago, USA between May 31st and June 4th. Madrid, June 4th, 2024.- PharmaMar (MSE:PHM) presented data from a Phase II trial evaluating PharmaMar’s lurbinectedin in combination with irinotecan in patients with relapsed Small Cell Lung Cancer (SCLC) after prior platinum-based treatment at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States. The results show that combining these two drugs produces a synergy that enhances the activity of lurbinectedin, resulting in high and durable response rates in populations that are sensitive, with a chemotherapy-free interval greater than 90 days (CTFI> 90 days), and platinum-resistant with a chemotherapy-free interval of less than 90 days (CTF< 90 days).  Particularly encouraging are the data drawn from the subgroup of 74 patients with a chemotherapy-free interval greater than 30 days (CTFI>30 days) with a response rate of 52.7% and a median response duration of 7.6 months. Among the study data within this subgroup, the overall survival (OS) data is also encouraging, with a median of 12.7 months. The safety profile has proven to be manageable with a low percentage of treatment interruptions. Dr. Luis Paz-Ares Rodríguez, Head of Medical Oncology at the “Hospital Universitario 12 de Octubre” commented: “although both irinotecan and lurbinectedin have demonstrated activity separately in monotherapy in SCLC, these compounds with different mechanisms of action have shown an important synergy when combined”. The encouraging results in the population referenced in the LAGOON trial (sensitive and resistant patients, CTFI>30d) reinforce the rationale for including this combination as an experimental arm with this type of patient in the ongoing pivotal trial.

The release as fetched from its publisher. pharmamar.com ↗